News

December 6, 2019December 6, 2019

Sutro’s Investigational Antibody-Drug Conjugate Shows Promise in Advanced Ovarian Cancer Phase 1 Trial

News

STRO-002, an investigational antibody-drug conjugate being developed by Sutro Biopharma, is safe and shows promising efficacy in women with advanced ovarian, fallopian tube, or primary peritoneal cancer, early Phase ... Read more

December 5, 2019December 9, 2019

China OKs Lynparza as Maintenance Therapy for Advanced Ovarian Cancers with BRCA Mutations

News

Oral Lynparza (olaparib) has been approved in China as a first-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer who responded to initial platinum-based chemotherapy, AstraZeneca and Merck (known as ... Read more

December 4, 2019

Rubraca Reimbursement Approved in Italy for Women With Relapsed Platinum-sensitive Ovarian Cancer

News

The Italian Medicines Agency (AIFA) has approved Clovis Oncology’s Rubraca (rucaparib) for reimbursement in Italy as a maintenance therapy for women with relapsed ovarian cancer who responded to platinum-based ... Read more

November 15, 2019

Ovarian Cancer Risk in Fertility Assistance Rises Mainly for Women with Endometriosis, Study Suggests

News

Women who require assisted reproductive technology to become mothers are not more likely to develop ovarian cancer, except for those with endometriosis, a new study suggests. The study, “Assisted ... Read more

November 13, 2019December 5, 2019

Opdivo-Avastin Combo Safe, Has Strong Activity in Relapsed Ovarian Cancer Patients, Phase 2 Trial Shows

News

A combination of Opdivo (nivolumab) and Avastin (bevacizumab) is safe and has strong clinical activity in women with relapsed ovarian cancer, especially among those whose tumors were sensitive to ... Read more

November 11, 2019

CA125 Blood Test May Help Alert GPs to Ovarian and Other Cancers, Research Shows

News

Commonly used in primary healthcare, blood tests for CA125 may help diagnose ovarian cancer and other types of cancer, particularly in older individuals, new research suggests. The findings were ... Read more

November 6, 2019

Syros’ SY-5609 Shows Promising Activity in OC Models, Supports Planned Phase 1 Trial, Results Show

News

Syros Pharmaceuticals‘ investigational oral inhibitor, SY-5609, can lead to a sustained inhibition of cancer growth in animal models of ovarian cancer and other solid tumors, preclinical data showed. The ... Read more

November 4, 2019

OTL38 ‘Lights up’ Ovarian Cancer Cells, Helping Surgeons to Remove Them, Phase 2 Study Shows

News

OTL38, a tumor-specific fluorescent compound that “lights up” ovarian tumor tissue during surgery, helped doctors to detect and remove cancer cells that would otherwise be missed, final results of ... Read more

November 1, 2019

Zejula Maintenance Increases Time Without Symptoms or Toxicity in Recurrent OC Patients, Study Says

News

Taking Zejula (niraparib) as a maintenance therapy may increase time without symptoms or toxicities from treatment in women with recurrent ovarian cancer, a new study found. These results suggest ... Read more

October 30, 2019October 30, 2019

Lynparza-Avastin First-Line Maintenance Therapy Delays Cancer Progression in Advanced OC, Phase 3 Study Shows

News

Adding Lynparza (olaparib) to Avastin (bevacizumab) as a first-line maintenance treatment significantly delayed disease progression in women with advanced ovarian cancer — regardless of BRCA mutation status — interim data from a ... Read more

Pin It on Pinterest